INBIOGEN (A101140) 주식 개요인바이오젠(주)는 한국에서 신발 제품을 제조 및 유통하는 기업입니다. 자세히 보기A101140 펀더멘털 분석스노우플레이크 점수가치 평가0/6미래 성장0/6과거 실적0/6재무 건전성4/6배당0/6위험 분석의미 있는 시가총액이 없습니다(₩67B)의미 있는 수익이 없습니다(₩6B)모든 위험 점검 보기A101140 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩6.64k2.4k% 고평가 내재 할인율Growth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-117b94b2016201920222025202620282031Revenue ₩3.3bEarnings ₩239.5mAdvancedSet Fair ValueView all narrativesINBIOGEN Co., Ltd. 경쟁사Black Yak I&CLtdSymbol: KOSDAQ:A478560Market cap: ₩81.0bHWASEUNG IndustriesLtdSymbol: KOSE:A006060Market cap: ₩141.8bDeep CommerceSymbol: KOSDAQ:A900110Market cap: ₩26.3bHwaseung EnterpriseSymbol: KOSE:A241590Market cap: ₩227.8b가격 이력 및 성과INBIOGEN 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가₩6,640.0052주 최고가₩14,700.0052주 최저가₩6,340.00베타0.761개월 변동-25.56%3개월 변동-39.08%1년 변동-40.56%3년 변동n/a5년 변동-90.09%IPO 이후 변동-97.57%최근 뉴스 및 업데이트New Risk • Apr 04New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.3b (US$4.2m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.2m). Market cap is less than US$100m (₩88.0b market cap, or US$58.2m).Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,800, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 10x in the Luxury industry in South Korea. Total loss to shareholders of 13% over the past three years.공시 • Mar 17INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South KoreaValuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩9,060, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 12x in the Luxury industry in South Korea. Total loss to shareholders of 25% over the past three years.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 24% over the past three years.New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩113.7b market cap, or US$78.7m).더 많은 업데이트 보기Recent updatesNew Risk • Apr 04New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.3b (US$4.2m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.2m). Market cap is less than US$100m (₩88.0b market cap, or US$58.2m).Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,800, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 10x in the Luxury industry in South Korea. Total loss to shareholders of 13% over the past three years.공시 • Mar 17INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South KoreaValuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩9,060, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 12x in the Luxury industry in South Korea. Total loss to shareholders of 25% over the past three years.Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 24% over the past three years.New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩113.7b market cap, or US$78.7m).분석 기사 • Nov 21Statutory Profit Doesn't Reflect How Good INBIOGEN's (KRX:101140) Earnings AreINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. We think that...Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Net income: ₩8.17b (up ₩12.6b from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩11,270, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 73% over the past three years.분석 기사 • May 22Solid Earnings Reflect INBIOGEN's (KRX:101140) Strength As A BusinessINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. Investors are...Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩12,380, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 72% over the past three years.Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₩12,620, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 74% over the past three years.Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,980, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 7x in the Luxury industry in South Korea. Total loss to shareholders of 89% over the past three years.공시 • Mar 13INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea분석 기사 • Jan 17Companies Like INBIOGEN (KRX:101140) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...New Risk • Jan 15New major risk - Revenue and earnings growthEarnings have declined by 1.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 1.9% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.4b revenue, or US$4.4m). Market cap is less than US$100m (₩66.8b market cap, or US$45.8m).Board Change • Jan 13No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Aug 09INBIOGEN Co., Ltd. announced that it expects to receive KRW 30.00000036 billion in fundingINBIOGEN CO.,Ltd announced a private placement of 15,957,447 convertible preferred shares at KRW 1,880 per share for gross proceeds of KRW 30,000,000,360 on August 8, 2022. The transaction will include participation from new investor Scan No. 1 Association. The transaction is by way of third party capital increase. The payment date for the shares is expected on October 28, 2022. The transaction has been approved by board of directors of the company. The preferred shares are registered and 100% convertible from October 29, 2023 - September 29, 2032. The convertible preferred shares are issued at 10% discount.Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩1,830, the stock trades at a trailing P/E ratio of 22.2x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 50% over the past three years.Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₩1,835, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 59% over the past three years.Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.공시 • Sep 01INBIOGEN CO.,Ltd announced that it has received KRW 15 billion in fundingOn August 31, 2021, INBIOGEN CO.,Ltd closed the transaction. The company issued KRW 15,000,000,000 in the transaction.공시 • Jun 01INBIOGEN CO.,Ltd announced that it has received KRW 23.300002 billion in funding from Bucket Studio Co., Ltd.On May 31, 2021, INBIOGEN CO.,Ltd (KOSE:A101140) closed the transaction.분석 기사 • Mar 26Is INBIOGENLtd (KRX:101140) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...공시 • Mar 18INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021, at 10:30 Korea Standard Time.Is New 90 Day High Low • Feb 18New 90-day low: ₩3,580The company is down 48% from its price of ₩6,860 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 17% over the same period.분석 기사 • Jan 31Introducing INBIOGENLtd (KRX:101140), A Stock That Climbed 95% In The Last Five YearsINBIOGEN CO.,Ltd ( KRX:101140 ) shareholders might understandably be very concerned that the share price has dropped...Is New 90 Day High Low • Jan 31New 90-day low: ₩3,600The company is down 46% from its price of ₩6,680 on 02 November 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.공시 • Dec 04BTONE CO.,Ltd announced that it expects to receive KRW 25.00000128 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of 4,340,278 registered convertible preferred stock at an issue price of KRW 5,760 per share for gross proceeds of KRW 25,000,001,280 on December 2, 2020. The transaction will include participation from JJ Fund. The company will raise funding through third party allotment. The preferred stock will be fully convertible into the 4,340,278 registered common stock of the company at a conversion price of KRW 5,760 per share. The conversion period of the preferred stock will be from February 19, 2022 to January 19, 2031. The preferred stock will be issued at discount of 10%. The transaction is expected to close on February 19, 2021 and expected date of issuance of new shares is March 05, 2021. The security issued in the transaction will be subject to hold period of one year. The transaction was approved by the board of directors of the company.공시 • Nov 26BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 7 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on November 25, 2020. The transaction will include participation from JJ 1 Fund. The bonds will mature on January 29, 2024 and will carry 1% interest coupon and 2% yield to maturity. The bonds will be fully convertible into the 2,762,812 registered common stock of the company at a conversion price of KRW 7,239 per share. The conversion period of the bonds will be from January 29, 2022 to December 29, 2023. The bonds will be issued at its par value. The transaction is expected to close on January 29, 2021 and subscription date is November 27, 2020. The transaction was approved by the board of directors of the company.Is New 90 Day High Low • Nov 04New 90-day high: ₩7,290The company is up 87% from its price of ₩3,900 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 10.0% over the same period.Is New 90 Day High Low • Oct 19New 90-day high: ₩4,570The company is up 25% from its price of ₩3,650 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 7.0% over the same period.공시 • Oct 17BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 6 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on October 16, 2020. The transaction will include participation from Hoyeon 3 Fund. The bonds will mature on November 30, 2023 and will not carry 1% interest coupon and 2% yield to maturity. The bonds will carry lump sum redemption on its maturity. The bonds will be fully convertible into the 5,357,621 registered common stock of the company at a conversion price of KRW 3,733 per share for 12.75% stakes in the company. The conversion period of the bonds will be from November 30, 2021 to October 30, 2023. The bonds will be issued at its par value. The transaction is expected to close on November 30, 2020 and subscription date will be October 21, 2020. The transaction was approved by the board of directors of the company.주주 수익률A101140KR LuxuryKR 시장7D-0.7%-3.8%-2.5%1Y-40.6%13.3%184.3%전체 주주 수익률 보기수익률 대 산업: A101140은 지난 1년 동안 13.3%의 수익을 기록한 KR Luxury 산업보다 저조한 성과를 냈습니다.수익률 대 시장: A101140은 지난 1년 동안 184.3%를 기록한 KR 시장보다 저조한 성과를 냈습니다.주가 변동성Is A101140's price volatile compared to industry and market?A101140 volatilityA101140 Average Weekly Movement10.2%Luxury Industry Average Movement7.2%Market Average Movement9.3%10% most volatile stocks in KR Market16.5%10% least volatile stocks in KR Market4.9%안정적인 주가: A101140는 지난 3개월 동안 KR 시장에 비해 주가 변동성이 크지 않았습니다.시간에 따른 변동성: A101140의 주간 변동성(10%)은 지난 1년 동안 안정적이었습니다.회사 소개설립직원 수CEO웹사이트1949n/aMoo-Hyung Choiwww.inbiogen.co.kr인바이오젠은 한국에서 신발 제품 제조 및 유통업을 영위하고 있습니다. 또한 목재 펠릿 유통, 키오스크, 식음료 사업에도 관여하고 있습니다. 이 회사는 이전에 비티원 주식회사로 알려졌습니다.더 보기INBIOGEN Co., Ltd. 기초 지표 요약INBIOGEN의 순이익과 매출은 시가총액과 어떻게 비교됩니까?A101140 기초 통계시가총액₩66.70b순이익 (TTM)-₩1.42b매출 (TTM)₩6.30b10.5x주가매출비율(P/S)-46.7x주가수익비율(P/E)A101140는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표A101140 손익계산서 (TTM)매출₩6.30b매출원가₩6.68b총이익-₩384.38m기타 비용₩1.03b순이익-₩1.42b최근 보고된 실적Dec 31, 2025다음 실적 발표일해당 없음주당순이익(EPS)-142.08총이익률-6.10%순이익률-22.53%부채/자본 비율0.3%A101140의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 09:40종가2026/05/22 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스INBIOGEN Co., Ltd.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Apr 04New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.3b (US$4.2m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.2m). Market cap is less than US$100m (₩88.0b market cap, or US$58.2m).
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,800, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 10x in the Luxury industry in South Korea. Total loss to shareholders of 13% over the past three years.
공시 • Mar 17INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
Valuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩9,060, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 12x in the Luxury industry in South Korea. Total loss to shareholders of 25% over the past three years.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 24% over the past three years.
New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩113.7b market cap, or US$78.7m).
New Risk • Apr 04New minor risk - Revenue sizeThe company makes less than US$5m in revenue. Total revenue: ₩6.3b (US$4.2m) This is considered a minor risk. Companies with a small amount of revenue are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Minor Risks Revenue is less than US$5m (₩6.3b revenue, or US$4.2m). Market cap is less than US$100m (₩88.0b market cap, or US$58.2m).
Valuation Update With 7 Day Price Move • Mar 17Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₩9,800, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 10x in the Luxury industry in South Korea. Total loss to shareholders of 13% over the past three years.
공시 • Mar 17INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2026, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
Valuation Update With 7 Day Price Move • Mar 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₩9,060, the stock trades at a trailing P/E ratio of 3.5x. Average trailing P/E is 12x in the Luxury industry in South Korea. Total loss to shareholders of 25% over the past three years.
Valuation Update With 7 Day Price Move • Jan 05Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩12,130, the stock trades at a trailing P/E ratio of 4.6x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 24% over the past three years.
New Risk • Jan 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.5% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Minor Risks Share price has been volatile over the past 3 months (8.5% average weekly change). Market cap is less than US$100m (₩113.7b market cap, or US$78.7m).
분석 기사 • Nov 21Statutory Profit Doesn't Reflect How Good INBIOGEN's (KRX:101140) Earnings AreINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. We think that...
Reported Earnings • Nov 19Third quarter 2025 earnings releasedThird quarter 2025 results: Net income: ₩8.17b (up ₩12.6b from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 105% per year but the company’s share price has fallen by 13% per year, which means it is significantly lagging earnings.
Valuation Update With 7 Day Price Move • Aug 15Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₩11,270, the stock trades at a trailing P/E ratio of 11.8x. Average trailing P/E is 9x in the Luxury industry in South Korea. Total loss to shareholders of 73% over the past three years.
분석 기사 • May 22Solid Earnings Reflect INBIOGEN's (KRX:101140) Strength As A BusinessINBIOGEN Co., Ltd. ( KRX:101140 ) just reported healthy earnings but the stock price didn't move much. Investors are...
Valuation Update With 7 Day Price Move • May 21Investor sentiment deteriorates as stock falls 15%After last week's 15% share price decline to ₩12,380, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 72% over the past three years.
Valuation Update With 7 Day Price Move • May 02Investor sentiment improves as stock rises 40%After last week's 40% share price gain to ₩12,620, the stock trades at a trailing P/E ratio of 7.8x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 74% over the past three years.
Valuation Update With 7 Day Price Move • Apr 08Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₩5,980, the stock trades at a trailing P/E ratio of 3.7x. Average trailing P/E is 7x in the Luxury industry in South Korea. Total loss to shareholders of 89% over the past three years.
공시 • Mar 13INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025INBIOGEN Co., Ltd., Annual General Meeting, Mar 31, 2025, at 10:00 Tokyo Standard Time. Location: conference room, geumcheon-gu, seoul South Korea
분석 기사 • Jan 17Companies Like INBIOGEN (KRX:101140) Can Afford To Invest In GrowthWe can readily understand why investors are attracted to unprofitable companies. For example, biotech and mining...
New Risk • Jan 15New major risk - Revenue and earnings growthEarnings have declined by 1.9% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 1.9% per year over the past 5 years. Minor Risks Revenue is less than US$5m (₩6.4b revenue, or US$4.4m). Market cap is less than US$100m (₩66.8b market cap, or US$45.8m).
Board Change • Jan 13No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
Board Change • Nov 16No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Aug 09INBIOGEN Co., Ltd. announced that it expects to receive KRW 30.00000036 billion in fundingINBIOGEN CO.,Ltd announced a private placement of 15,957,447 convertible preferred shares at KRW 1,880 per share for gross proceeds of KRW 30,000,000,360 on August 8, 2022. The transaction will include participation from new investor Scan No. 1 Association. The transaction is by way of third party capital increase. The payment date for the shares is expected on October 28, 2022. The transaction has been approved by board of directors of the company. The preferred shares are registered and 100% convertible from October 29, 2023 - September 29, 2032. The convertible preferred shares are issued at 10% discount.
Valuation Update With 7 Day Price Move • Jul 08Investor sentiment improved over the past weekAfter last week's 16% share price gain to ₩1,830, the stock trades at a trailing P/E ratio of 22.2x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 50% over the past three years.
Valuation Update With 7 Day Price Move • Jun 20Investor sentiment deteriorated over the past weekAfter last week's 20% share price decline to ₩1,835, the stock trades at a trailing P/E ratio of 22.3x. Average trailing P/E is 8x in the Luxury industry in South Korea. Total loss to shareholders of 59% over the past three years.
Board Change • Apr 27No independent directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 6 experienced directors. No highly experienced directors. No independent directors (6 non-independent directors). was the last director to join the board, commencing their role in . The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment.
공시 • Sep 01INBIOGEN CO.,Ltd announced that it has received KRW 15 billion in fundingOn August 31, 2021, INBIOGEN CO.,Ltd closed the transaction. The company issued KRW 15,000,000,000 in the transaction.
공시 • Jun 01INBIOGEN CO.,Ltd announced that it has received KRW 23.300002 billion in funding from Bucket Studio Co., Ltd.On May 31, 2021, INBIOGEN CO.,Ltd (KOSE:A101140) closed the transaction.
분석 기사 • Mar 26Is INBIOGENLtd (KRX:101140) Using Debt In A Risky Way?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
공시 • Mar 18INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021INBIOGEN CO.,Ltd, Annual General Meeting, Mar 31, 2021, at 10:30 Korea Standard Time.
Is New 90 Day High Low • Feb 18New 90-day low: ₩3,580The company is down 48% from its price of ₩6,860 on 20 November 2020. The South Korean market is up 22% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 17% over the same period.
분석 기사 • Jan 31Introducing INBIOGENLtd (KRX:101140), A Stock That Climbed 95% In The Last Five YearsINBIOGEN CO.,Ltd ( KRX:101140 ) shareholders might understandably be very concerned that the share price has dropped...
Is New 90 Day High Low • Jan 31New 90-day low: ₩3,600The company is down 46% from its price of ₩6,680 on 02 November 2020. The South Korean market is up 29% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Luxury industry, which is up 14% over the same period.
공시 • Dec 04BTONE CO.,Ltd announced that it expects to receive KRW 25.00000128 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of 4,340,278 registered convertible preferred stock at an issue price of KRW 5,760 per share for gross proceeds of KRW 25,000,001,280 on December 2, 2020. The transaction will include participation from JJ Fund. The company will raise funding through third party allotment. The preferred stock will be fully convertible into the 4,340,278 registered common stock of the company at a conversion price of KRW 5,760 per share. The conversion period of the preferred stock will be from February 19, 2022 to January 19, 2031. The preferred stock will be issued at discount of 10%. The transaction is expected to close on February 19, 2021 and expected date of issuance of new shares is March 05, 2021. The security issued in the transaction will be subject to hold period of one year. The transaction was approved by the board of directors of the company.
공시 • Nov 26BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 7 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on November 25, 2020. The transaction will include participation from JJ 1 Fund. The bonds will mature on January 29, 2024 and will carry 1% interest coupon and 2% yield to maturity. The bonds will be fully convertible into the 2,762,812 registered common stock of the company at a conversion price of KRW 7,239 per share. The conversion period of the bonds will be from January 29, 2022 to December 29, 2023. The bonds will be issued at its par value. The transaction is expected to close on January 29, 2021 and subscription date is November 27, 2020. The transaction was approved by the board of directors of the company.
Is New 90 Day High Low • Nov 04New 90-day high: ₩7,290The company is up 87% from its price of ₩3,900 on 06 August 2020. The South Korean market is up 1.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 10.0% over the same period.
Is New 90 Day High Low • Oct 19New 90-day high: ₩4,570The company is up 25% from its price of ₩3,650 on 21 July 2020. The South Korean market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Luxury industry, which is up 7.0% over the same period.
공시 • Oct 17BTONE CO.,Ltd announced that it expects to receive KRW 20 billion in fundingBTONE CO.,Ltd (KOSE:A101140) announced a private placement of series 6 Non-guaranteed private convertible bonds with bearer interest for gross proceeds of KRW 20,000,000,000 on October 16, 2020. The transaction will include participation from Hoyeon 3 Fund. The bonds will mature on November 30, 2023 and will not carry 1% interest coupon and 2% yield to maturity. The bonds will carry lump sum redemption on its maturity. The bonds will be fully convertible into the 5,357,621 registered common stock of the company at a conversion price of KRW 3,733 per share for 12.75% stakes in the company. The conversion period of the bonds will be from November 30, 2021 to October 30, 2023. The bonds will be issued at its par value. The transaction is expected to close on November 30, 2020 and subscription date will be October 21, 2020. The transaction was approved by the board of directors of the company.
